Dr. Li Discusses the PROFILE Crizotinib Clinical Trials

Tianhong Li, MD, PhD
Published: Thursday, Sep 01, 2011

Tianhong (Tina) Li, MD, PhD, assistant professor, co-director of Phase I Program, UC Davis Cancer Center, discusses the PROFILE clinical trials examining ALK-positive non-small cell lung cancer patients that led to the FDA approval of Pfrizer's crizotinib (Xalkori).

The 1001 trial examined 119 ALK-positive NSCLC patients with a 61% overall response rate and 69% partial response rates. The 1005 trial also exhibited great results, with 136 patients and a 50% overall response rate, including 1 complete response and 67% partial response.
Tianhong (Tina) Li, MD, PhD, assistant professor, co-director of Phase I Program, UC Davis Cancer Center, discusses the PROFILE clinical trials examining ALK-positive non-small cell lung cancer patients that led to the FDA approval of Pfrizer's crizotinib (Xalkori).

The 1001 trial examined 119 ALK-positive NSCLC patients with a 61% overall response rate and 69% partial response rates. The 1005 trial also exhibited great results, with 136 patients and a 50% overall response rate, including 1 complete response and 67% partial response.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x